• LAST PRICE
    36.6000
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    36.0000/ 1
  • Ask / Lots
    37.1000/ 5
  • Open / Previous Close
    37.2200 / 36.6000
  • Day Range
    Low 36.2400
    High 37.3800
  • 52 Week Range
    Low 27.9850
    High 50.9900
  • Volume
    487,700
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 37.25
TimeVolumeXENE
09:32 ET145337.22
09:34 ET30037.17
09:38 ET20037.02
09:48 ET30036.77
09:52 ET45036.97
09:56 ET60037.05
09:57 ET10037.055
09:59 ET10037.15
10:01 ET20037.115
10:03 ET90037.2
10:06 ET30737.05
10:08 ET12437.08
10:14 ET50537.37
10:17 ET18237.38
10:19 ET10037.2
10:21 ET10037.295
10:28 ET11337.21
10:30 ET10037.295
10:39 ET20037.265
10:42 ET30637.12
10:51 ET160037.27
10:53 ET40037.26
10:55 ET10037.27
11:00 ET40037.28
11:02 ET50037.26
11:06 ET126637.175
11:08 ET549536.84
11:09 ET958036.88
11:11 ET40036.79
11:13 ET40036.56
11:15 ET30036.59
11:18 ET225036.53
11:20 ET30036.51
11:22 ET10036.51
11:24 ET100836.47
11:26 ET240036.38
11:27 ET20036.36
11:29 ET200236.38
11:31 ET100036.34
11:33 ET20036.34
11:36 ET40036.36
11:38 ET30036.4
11:40 ET50036.39
11:45 ET258836.5
11:47 ET33636.58
11:49 ET10036.54
11:54 ET10036.53
11:56 ET10036.52
12:03 ET50036.5
12:05 ET10036.5
12:09 ET10036.48
12:12 ET10036.47
12:16 ET212136.46
12:18 ET21936.5328
12:20 ET80036.55
12:21 ET10036.59
12:23 ET10036.51
12:30 ET10036.63
12:34 ET20036.63
12:39 ET80036.47
12:41 ET50036.4
12:43 ET20036.43
12:45 ET60036.44
12:48 ET20036.47
12:52 ET40036.41
12:59 ET20036.41
01:06 ET227236.5
01:08 ET90036.38
01:10 ET10036.465
01:12 ET10036.465
01:26 ET100036.38
01:33 ET101836.46
01:35 ET22436.46
01:37 ET30036.44
01:39 ET10036.47
01:42 ET100036.62
01:44 ET10036.63
01:46 ET35436.625
01:50 ET10036.645
01:51 ET310036.8
01:53 ET10036.85
01:55 ET430036.92
02:02 ET30236.97
02:04 ET183136.93
02:06 ET40036.9
02:08 ET3143136.83
02:09 ET88236.83
02:11 ET130036.87
02:13 ET10336.89
02:15 ET271836.88
02:18 ET80036.89
02:20 ET273136.775
02:22 ET20036.755
02:24 ET10036.755
02:26 ET160736.56
02:27 ET191936.73
02:29 ET20036.73
02:31 ET20036.71
02:33 ET30036.72
02:36 ET1562736.6
02:38 ET63636.66
02:40 ET10036.55
02:42 ET60036.56
02:45 ET20036.52
02:47 ET42136.45
02:49 ET10036.44
02:51 ET10036.55
02:56 ET332936.585
02:58 ET120836.59
03:00 ET125536.65
03:05 ET291936.69
03:07 ET510036.63
03:09 ET10036.64
03:12 ET10036.66
03:14 ET20036.69
03:16 ET70036.65
03:20 ET41736.69
03:21 ET20036.705
03:23 ET110036.75
03:25 ET302236.63
03:27 ET60036.63
03:30 ET100036.67
03:32 ET50036.64
03:34 ET60036.65
03:36 ET231336.55
03:38 ET30436.58
03:39 ET156536.57
03:41 ET70036.56
03:43 ET350936.43
03:45 ET70036.36
03:48 ET40036.35
03:50 ET90136.35
03:52 ET370036.3
03:54 ET421236.32
03:56 ET771036.43
03:57 ET473236.52
03:59 ET9866836.6
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesXENE
Xenon Pharmaceuticals Inc
2.8B
-13.5x
---
United StatesGPCR
Structure Therapeutics Inc
2.7B
-20.9x
---
United StatesGERN
Geron Corp
2.9B
-13.5x
---
United StatesSWTX
SpringWorks Therapeutics Inc
2.9B
-7.1x
---
United StatesMLTX
MoonLake Immunotherapeutics
2.6B
-53.6x
---
United StatesBHVN
Biohaven Ltd
3.0B
-4.8x
---
As of 2024-06-18

Company Information

Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).

Contact Information

Headquarters
3650 Gilmore WayVANCOUVER, BC, Canada V5G 4W8
Phone
604-484-3300
Fax
604-484-3450

Executives

Chairman of the Board
Simon Pimstone
President, Chief Executive Officer, Director
Ian Mortimer
Chief Financial Officer
Sherry Aulin
Executive Vice President - Drug Discovery
James Empfield
Executive Vice President - Strategy and Innovation
Robin Sherrington

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$2.8B
Revenue (TTM)
$0.00
Shares Outstanding
75.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.26
EPS
$-2.71
Book Value
$12.31
P/E Ratio
-13.5x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.